2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

www.kumc.edu

 

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium
D

The Use of IO Agents in Metastatic NSCLC: Overview of Anti-PD-1/Anti-PD-L1 Agents and Their Combinations, and Outcomes of Pivotal Trials

By 2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium FEATURING Don Gibbons
By 2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium FEATURING Don Gibbons
846 views
November 12, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Featured Video

13:36
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss
Lung
17:19

The Use of IO Agents in Metastatic NSCLC: Overview of Anti-PD-1/Anti…

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

D. Gibbons

846 views
10:16

Immunotherapy in Advanced NSCLC: Difficulties With Biomarkers Develo…

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

D. Gibbons

89 views
13:33

Checkpoint Inhibitors in Stage III NSCLC (Pacific Trial Regimen) / B…

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

D. Gibbons

129 views
17:11

Microbiome as a Predictive Ecosystem for Immunotherapy in NSCLC Can …

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

J. Zhang

38 views
12:42

New KRAS G12C / MET Exon 14 TKI’s for Advanced NSCLC: Favorable Safe…

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

C. Huang

430 views
22:41

New TKI’s in Development for Lung Cancer. An Overview of New ROS1 / …

2019 University of Kansas Lung Cancer and Head & Neck Cancer Symposium

C. Huang

338 views